Istanbul Police Crackdown on Fake Cancer Drug Gang
Istanbul police have raided an organised crime gang that had been selling counterfeit cancer drugs in Turkey and abroad, in an operation carried out in nine separate cities.
The gang had been manufacturing the counterfeit drugs and selling them to both domestic and foreign health institutions, including in the US.
The police operation started on 10 December in around 130 places across nine cities, resulting in the detention of 56 suspects.
Some 37 suspects were detained in Istanbul and later sent to the Police General Directorate for questioning on 11 December. Those detained in other cities were also expected to be brought to Istanbul.
As part of the crackdown, police raided a printing house in the Bağcılar district, where gang members had been printing the box and the prospectus of the counterfeit drugs. Fake passports and a gun were also found at the printing house and seized, Cihan news agency reported.
The gang was packaging drugs that had extended their use-by date as if they were new and reselling them to patients. One packet of these drugs was being sold for between 2000 and 2500 Turkish Liras.
The gang had also manufactured counterfeit version of around 30 different drugs, among them drugs used to treat cancer.
It has been revealed that 95 cancer patients had used these drugs and had been warned. The health condition of these patients deteriorated after taking the counterfeit pills. All have now filed a formal complaint against those who sold them the counterfeit drugs.
The gang was particularly focusing on the production of drugs that are scarce in pharmacies, offering them to patients illegally without any form of official paperwork.
Five hospital workers who were allegedly acting as suppliers of the counterfeit drugs to patients have been detained in Istanbul, and police are still searching for two doctors believed to have also been involved. The gang was reportedly bribing the doctors and hospital personnel in order to access patients for the sale of the counterfeit drugs.
The gang was exposed following scrutiny of the fake drugs’ packaging by a nurse at state-run Şişli Etfal Education and Research Hospital. After the nurse realized that the contents differed slightly different from the original, she was prompted to follow up the licensing of the drug. The expiration date of the drug had been recorded as 2013 in the system, while the drug’s packaging showed 2014. The drug was sent to the manufacturer, where it was identified as a counterfeit drug, containing unhealthy chemicals.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance